Prostate Cancer News Archive: 28-Feb-2006

• Fosamax cuts bone loss in men with prostate cancer (Reuters via Yahoo! News)
  Testosterone-lowering therapy -- one of the most effective and commonly used therapies for prostate cancer -- often causes bone loss. However, once-weekly drug treatment combats the problem, according to a new study.



• Delayed Prostate Cancer Surgery Poses No Increased Risk for Some Patients (Newswise)
  Delaying surgery -- even for years -- for patients with small, low-grade prostate cancer does not appear to increase the risk of the disease progressing to an incurable form, according to a 10-year Johns Hopkins Medicine study.



• Prostate Cancer: What Men Must Know About PSA Test (Fox News)
  Early detection of prostate cancer saves lives, the the PSA test can lead to unnecessary alarm and biopsies.



• Delayed intervention may combat overtreatment of prostate cancer, study suggests (EurekAlert!)
  Delayed surgical treatment for patients with small, low-grade prostate cancer tumors was not associated with lowered curability, according to a study in the March 1 issue of the Journal of the National Cancer Institute.



• Prostate Cancer: Treatment Options Explained (Fox News)
  Deciding which treatment option to pursue for prostate cancer can be confusing; here, the different treatments and procedures explained.



• Fosamax cuts bone loss in men with prostate cancer (Reuters via Yahoo! Australia & NZ Health)
  NEW YORK (Reuters Health) - Testosterone-lowering therapy -- one of the most effective and commonly used therapies for prostate cancer -- often causes bone loss.

Back to Prostate Cancer News Archives